Ditch #complicated #remdesivir #Patent2017 and focus on #GS441524 #Simpler #Safer #ancestor #Patent2009?

The following news is highly technical #Chemical #Pharmaceutical #Covid19 science. If I may share with you my trick and general approach to learning: I often try to read something and understand it as much as I can KNOWING I don’t know a LOT. Knowing what questions to ask and what we don’t know is part way to understanding/”some minor progress in understanding” new cutting edge science. To quote a Quote I LOVE by the Nobel Economist Ronald Coase when he was 100 years old, “You don’t know what you can learn until you try to learn.”

Have a read of May 14, 2020, Stat News, “Gilead should ditch remdesivir and focus on its simpler and safer ancestor” By Victoria C. Yan and Florian L. Muller  [HT Gabriel @gmleunghku for his RT this morning, I saw the STAT News op-ed but his RT put it more on my radar]

Here is an excerpt from //Opinion: Gilead has another antiviral that’s easier to make and safer to use than remdesivir. Why isn’t it giving that drug any attention? The world can only hope it isn’t for the sake of protecting its intellectual property.//

“The attractive profile of GS-441524 from both manufacturing and clinical perspectives raises this question: Why hasn’t Gilead opted to advance this compound to the clinic? We would be remiss for not mentioning patents, and thus profits. The first patent on GS-441524 was issued in 2009, while the first patent for remdesivir was issued in 2017.

We aren’t the only ones questioning Gilead’s strategy. We have spoken with a number of chemists, biochemists, veterinarians, and others who are also surprised that GS-441524 has remained out of the spotlight. Veterinarians we spoke to have noted that the strong antiviral activity of GS-441524 has resulted in a “miraculous turn of events” for cats infected with feline coronavirus, which was once considered a death sentence.

Given GS-441524’s optimal properties, we — along with the millions of people awaiting an effective treatment for Covid-19 — are left to wonder why Gilead isn’t giving it the same attention it is giving remdesivir. The world can only hope it isn’t for the sake of protecting its intellectual property.”

[NOTE: Do NOT take experts’ words blindly but let them highlight potentially interesting questions or where cutting edge science is]

P,S, In the 90s, I, for no good reasons that I can remember and may be I had too much money to waste/spend, subscribed to The New England Journal of Medicine for one full year! May be it was to broaden my understanding of medical science, better armed myself to read medical research, or simply to reduce my fear of reading research papers that I really know very little! I particular enjoy, if I remember right, reading the concluding paragraphs of many research papers talking about what’s “NEXT” for the researchers, what were their “unknowns”!

Gilead should ditch remdesivir and focus on its simpler and safer ancestor - pix

Gilead should ditch remdesivir and focus on its simpler and safer ancestor – pix

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: